Dr Angray Kang, BSc (Hons), PhD
Reader in Molecular Cell Biology
Email: email@example.comTelephone: +44 20 7882 7158Room Number: Blizard Building
1979-83 Kings (Chelsea College) University of London B.Sc. Microbiology 1st Class Honours.
1983-86 University of East Anglia Ph.D. Biochemistry (Institute of Food Research Norwich, supervisor Prof. Henry W-S. Chan). The research was supported by an AFRC studentship and directed towards generating antibodies against mycotoxins (aflatoxin & sterigmatocystin) and developing non-isotopic immunoassays.
1986-87 Post doctoral research (SERC) at University of Durham UK with Professor Don Boulter.
1987-89 Post doctoral research (SERC) at University of Sheffield UK with Professor Dennis Burton.
1989-90 Visiting post doctoral researcher at The Scripps Research Institute with Professor Richard A. Lerner.
1990-1999 Assistant Professor Molecular Biology, The Scripps Research Institute.
Between 1999 and the return to academia in 2005 held various posts of increasing responsibility in drug discovery and development in biopharmaceutical companies (Abgenix Inc, Diversa Corporation and Avanir Pharmaceuticals).
2005-2011 Reader in Molecular Applied Biosciences at the University of Westminster.
2011- present Reader in Molecular Cell Biology Queen Mary University of London.
Google Scholar Citations
Vaccination offers protection against many pathogens, but it is increasingly recognized that towards the end of the the 20th century, successes of the past may be difficult to attain for all pathogens. Viruses which are highly mutable such as HIV-1 and HCV, to date have proved difficult "moving" targets. In other cases vaccines may be effective but the timelines required to build up immunity are long as is the case with anthrax vaccine adsorbed (AVA). Parasites such as Plasmodium falciparum and Trypanosoma cruzi, the causative agents of malaria and Chagas' disease respectively, have also proved to be challenging targets for vaccine development.
An alternative approach is to look at individuals exposed to either the pathogen or a vaccine and decipher the antibody response and to attempt to identify what may be protective antibodies for use in passive immunisation or to aid the design of vaccines based on conserved protective structures or even use the genetically encoded antibodies in novel interventions.
In order to do undertake such molecular dissection of the antibody response requires the development and application of enabling molecular display technologies.
Tang J, Wang L, Markiv A, Jeffs SA, Dreja H, McKnight A, He M, Kang AS. Accessing of recombinant human monoclonal antibodies from patient libraries by eukaryotic ribosome display. Human Antibodies. 2012 in press.
Azizi A, Arora A, Markiv A, Lampe DJ, Miller T, Kang AS. Ribosome Display of Combinatorial Antibody Libraries Derived From Mice Immunised With Heat-Killed Xylella fastidiosa and the Selection of MopB-Specific Single-Chain Antibodies. Appl Environ Microbiol. 2012 Apr;78(8):2638-47.
Markiv A, Beatson R, Burchell J, Durvasula RV, Kang AS. Expression of recombinant multi-coloured fluorescent antibodies in gor -/ trxB- E. coli cytoplasm. BMC Biotechnol. 2011 Nov 30;11(1):117.
Fang W, Vega-Rodríguez J, Ghosh AK, Jacobs-Lorena M, Kang A, St Leger RJ. Development of transgenic fungi that kill human malaria parasites in mosquitoes. Science. 2011 Feb 25;331(6020):1074-7.
Markiv A, Anani B, Durvasula RV, Kang AS. Module based antibody engineering: a novel synthetic REDantibody. J Immunol Methods. 2011 Feb 1;364(1-2):40-9.